Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context

References

• Sadleir LG, Scheffer IE. Febrile seizures. BMJ. 2007;334(7588):307–311. doi: 10.1136/bmj.39087.691817.AE
   PubMedGoogle Scholar
• Smith DK, Sadler KP, Benedum M. Febrile seizures: risks, evaluation, and prognosis. Am Fam Physician. 2019;99(7):445–450.
   PubMed Web of Science ®Google Scholar
• Steering Committee on Quality Improvement Management; Subcommittee on Febrile Seizures. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics. 2008;121(6):1281–1286. doi: 10.1542/peds.2008-0939
   PubMed Web of Science ®Google Scholar
• Mewasingh LD, Chin RFM, Scott RC. Current understanding of febrile seizures and their long-term outcomes. Dev Med Child Neurol. 2020;62(11):1245–1249. doi: 10.1111/dmcn.14642
   PubMed Web of Science ®Google Scholar
• Bethune P, Gordon K, Dooley J, et al. Which child will have a febrile seizure? Am J Dis Child. 1993;147(1):35–39. doi: 10.1001/archpedi.1993.02160250037013
   PubMedGoogle Scholar
• Laino D, Mencaroni E, Esposito S. Management of pediatric febrile seizures. Int J Environ Res Public Health. 2018;15(10):2232. doi: 10.3390/ijerph15102232
   PubMed Web of Science ®Google Scholar
• Naveed Ur R, Billoo AG. Association between iron deficiency anemia and febrile seizures. J Coll Physicians Surg Pak. 2005;15(6):338–340.
   PubMedGoogle Scholar
• Chiu SS, Tse CY, Lau YL, et al. Influenza a infection is an important cause of febrile seizures. Pediatrics. 2001;108(4):E63. doi: 10.1542/peds.108.4.e63
   PubMed Web of Science ®Google Scholar
• Chung B, Wong V. Relationship between five common viruses and febrile seizure in children. Arch Dis Child. 2007;92(7):589–593. doi: 10.1136/adc.2006.110221
   PubMed Web of Science ®Google Scholar
• Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331(7):432–438. doi: 10.1056/NEJM199408183310703
   PubMed Web of Science ®Google Scholar
• Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004;189 Suppl 1(Supplement_1):S4–16. doi: 10.1086/377712
   PubMedGoogle Scholar
• Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28(44):7215–7220. doi: 10.1016/j.vaccine.2010.08.062
   PubMed Web of Science ®Google Scholar
• Armstrong PK, Dowse GK, Effler PV, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011;1(1):e000016. doi: 10.1136/bmjopen-2010-000016
   PubMed Web of Science ®Google Scholar
• Duffy J, Hambidge SJ, Jackson LA, et al. Febrile seizure risk after vaccination in children one to five months of age. Pediatr Neurol. 2017;76:72–78. doi: 10.1016/j.pediatrneurol.2017.08.005
   PubMed Web of Science ®Google Scholar
• Duffy J, Weintraub E, Hambidge SJ, et al. Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics. 2016;138(1):e20160320. doi: 10.1542/peds.2016-0320
   PubMed Web of Science ®Google Scholar
• Gavrielov-Yusim N, Hoshen M, Singer SR, et al. The weight of MMRV-related febrile convulsions among other clinical factors contributing to febrile convulsions in children. Vaccine. 2014;32(39):4954–4959. doi: 10.1016/j.vaccine.2014.07.024
   PubMed Web of Science ®Google Scholar
• Hall GC, Douglas I, Heath PT, et al. Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program. Vaccine. 2021;39(24):3296–3303. doi: 10.1016/j.vaccine.2021.02.065
   PubMed Web of Science ®Google Scholar
• Leung AK, Hon KL, Leung TN. Febrile seizures: an overview. Drugs Context. 2018;7:212536. doi: 10.7573/dic.212536
   PubMedGoogle Scholar
• Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type B. JAMA. 2012;307(8):823–831. doi: 10.1001/jama.2012.165
   PubMed Web of Science ®Google Scholar
• Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the vaccine safety datalink project, 2010–2011. Vaccine. 2012;30(11):2024–2031. doi: 10.1016/j.vaccine.2012.01.027
   PubMed Web of Science ®Google Scholar
• Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4(4):CD004407. doi: 10.1002/14651858.CD004407.pub4
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656–4661. doi: 10.1016/j.vaccine.2009.05.056
   PubMed Web of Science ®Google Scholar
• Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–8. doi: 10.1542/peds.2010-0665
   PubMed Web of Science ®Google Scholar
• MacDonald SE, Dover DC, Simmonds KA, et al. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ. 2014;186(11):824–829. doi: 10.1503/cmaj.140078
   PubMed Web of Science ®Google Scholar
• Schink T, Holstiege J, Kowalzik F, et al. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645–650. doi: 10.1016/j.vaccine.2013.12.011
   PubMed Web of Science ®Google Scholar
• Streng A, Liese JG. Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles–mumps–rubella. Vaccine. 2014; 32(8):897–900. doi: 10.1016/j.vaccine.2013.12.065
   PubMed Web of Science ®Google Scholar
• Gontko-Romanowska K, Żaba Z, Panieński P, et al. The assessment of risk factors for febrile seizures in children. Neurol Neurochir Pol. 2017;51(6):454–458. doi: 10.1016/j.pjnns.2017.07.011
   PubMed Web of Science ®Google Scholar
• Sharawat IK, Singh J, Dawman L, et al. Evaluation of risk factors associated with first episode febrile seizure. J Clin Diagn Res. 2016;10(5):SC10–13. doi: 10.7860/JCDR/2016/18635.7853
   PubMedGoogle Scholar
• National Institute of Neurological Disorders and Stroke. Febrile seizures fact sheet. [cited 2021 Sep 2]. Available from: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Febrile-Seizures-Fact-Sheet.
   Google Scholar
• Offringa M, Bossuyt PM, Lubsen J, et al. Risk factors for seizure recurrence in children with febrile seizures: a pooled analysis of individual patient data from five studies. J Pediatr. 1994;124(4):574–584. doi: 10.1016/S0022-3476(05)83136-1
   PubMed Web of Science ®Google Scholar
• Waruiru C, Appleton R. Febrile seizures: an update. Arch Dis Child. 2004;89(8):751–756. doi: 10.1136/adc.2003.028449
   PubMed Web of Science ®Google Scholar
• Verbeek NE, Jansen FE, Vermeer-de Bondt PE, et al. Etiologies for seizures around the time of vaccination. Pediatrics. 2014;134(4):658–666. doi: 10.1542/peds.2014-0690
   PubMed Web of Science ®Google Scholar
• Verbeek NE, van der Maas NA, Sonsma AC, et al. Effect of vaccinations on seizure risk and disease course in Dravet syndrome. Neurology. 2015;85(7):596–603. doi: 10.1212/WNL.0000000000001855
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases. Febrile seizures: guideline for the neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011;127(2):389–394. doi: 10.1542/peds.2010-3318
   PubMed Web of Science ®Google Scholar
• National Health Service. Febrile seizures. [cited 2021 Sep 22]. Available from: https://www.nhs.uk/conditions/febrile-seizures/.
   Google Scholar
• Natsume J, Hamano SI, Iyoda K, et al. New guidelines for management of febrile seizures in japan. Brain Dev. 2017;39(1):2–9. doi: 10.1016/j.braindev.2016.06.003
   PubMed Web of Science ®Google Scholar
• Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;2012(2):CD004407. doi: 10.1002/14651858.CD004407.pub3
   PubMedGoogle Scholar
• Australian Government-Department of Health and Aged Care. National immunisation program schedule. [cited 2022 Sep 20]. Available from: https://www.health.gov.au/health-topics/immunisation/when-to-get-vaccinated/national-immunisation-program-schedule.
   Google Scholar
• Government of Canada. Measles vaccine: Canadian immunization guide. [cited 2022 Sep 20]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-12-measles-vaccine.html.
   Google Scholar
• Robert-Koch-Institut. Masern. RKI-Ratgeber. [cited 2022 Jan 14]. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Masern.html.
   Google Scholar
• Czajka H, Schuster V, Zepp F, et al. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): immunogenicity and safety profile. Vaccine. 2009;27(47):6504–6511. doi: 10.1016/j.vaccine.2009.07.076
   PubMed Web of Science ®Google Scholar
• Kuter BJ, Hoffman Brown ML, Hartzel J, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2(5):205–214. doi: 10.4161/hv.2.5.3246
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. ACIP provisional recommendations for prevention of varicella. [cited 2022 Jul 25]. Available from: https://oeps.wv.gov/varicella/documents/lhd/varicella_acip_recs_prov.pdf.
   Google Scholar
• CDC. Licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR Weekly. 2005;54(47):1212–1214.
   Google Scholar
• Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR–4):1–40.
   PubMedGoogle Scholar
• European Medicines Agency. ProQuad. [cited 2021 Sep 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/proquad.
   Google Scholar
• Robert-Koch-Institut. Impfung gegen Varizellen im Kindesalter: Empfehlung einer zweiten Varizellenimpfung Empfehlung und Begründung. [cited 2022 Jul 25]. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2009/Ausgaben/32_09.pdf?__blob=publicationFile.
   Google Scholar
• Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809–814. doi: 10.1542/peds.2011-3198
   PubMed Web of Science ®Google Scholar
• Ma SJ, Xiong YQ, Jiang LN, et al. Risk of febrile seizure after measles–mumps–rubella–varicella vaccine: a systematic review and meta-analysis. Vaccine. 2015;33(31):3636–3649. doi: 10.1016/j.vaccine.2015.06.009
   PubMed Web of Science ®Google Scholar
• Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR–3):1–12.
   PubMedGoogle Scholar
• Robert-Koch-Institut. Zur kombinationsimpfung gegen masern, mumps röteln und varizellen (MMRV). Epidemiologisches Bull. 2011;38:352–353.
   Google Scholar
• AIFA - Working Group Pediatrico. Raccomandazioni del working group pediatrico dell’AIFA in relazione all’ utilizzo dei vaccini MPRV. [cited 2021 Sep 22]. Available from: https://www.aifa.gov.it/sites/default/files/raccomandazione_vaccino_mprv_14_novembre_2011.pdf.
   Google Scholar
• Stefanizzi P, Stella P, Ancona D, et al. Adverse events following measles-mumps-rubella-varicella vaccination and the case of seizures: a post marketing active surveillance in Puglia Italian region, 2017-2018. Vaccines (Basel). 2019;7(4):140. doi: 10.3390/vaccines7040140
   PubMed Web of Science ®Google Scholar
• Vitali Rosati G. Chickenpox vaccination. Ital J Pediatr. 2014;40(S1):A3. doi: 10.1186/1824-7288-40-S1-A3
   PubMedGoogle Scholar
• Deng L, Wood N, Danchin M. Seizures following vaccination in children: risks, outcomes and management of subsequent revaccination. Aust J Gen Pract. 2020;49(10):644–649. doi: 10.31128/AJGP-02-20-5236
   PubMed Web of Science ®Google Scholar
• Ahern S, Walsh KA, Paone S, et al. Safety of varicella vaccination strategies: an overview of reviews. Rev Med Virol. 2023;33(2):e2416. doi: 10.1002/rmv.2416
   PubMed Web of Science ®Google Scholar
• McClure DL, Jacobsen SJ, Klein NP, et al. Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine. 2019;37(1):76–79. doi: 10.1016/j.vaccine.2018.11.038
   PubMed Web of Science ®Google Scholar
• Stefanizzi P, De Nitto S, Patano F, et al. Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospective study in Apulia region (ITALY), 2009-2017. Hum Vaccin Immunother. 2020;16(8):1875–1883. doi: 10.1080/21645515.2019.1704124
   PubMed Web of Science ®Google Scholar
• Cocchio S, Zanoni G, Opri R, et al. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. Hum Vaccin Immunother. 2016;12(3):651–654. doi: 10.1080/21645515.2015.1101198
   PubMed Web of Science ®Google Scholar
• Klopfer SO, Stek JE, Petrecz M, et al. Analysis of safety data in children after receiving two doses of ProQuad® (MMRV). Vaccine. 2014;32(52):7154–7160. doi: 10.1016/j.vaccine.2014.08.067
   PubMed Web of Science ®Google Scholar
• Woo EJ, Winiecki SK, Arya D, et al. Adverse events after MMR or MMRV vaccine in infants under nine months old. Pediatr Infect Dis J. 2016;35(8):e253–257. doi: 10.1097/INF.0000000000001201
   PubMed Web of Science ®Google Scholar
• Klein NP, Zerbo O, Goddard K, et al. Genetic associations with a fever after measles-containing vaccines. Hum Vaccin Immunother. 2021;17(6):1763–1769. doi: 10.1080/21645515.2020.1849520
   PubMed Web of Science ®Google Scholar
• Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27(3):446–453. doi: 10.1016/j.vaccine.2008.10.064
   PubMed Web of Science ®Google Scholar
• Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007;35(5):326–333. doi: 10.1007/s15010-007-6337-z
   PubMed Web of Science ®Google Scholar
• Knuf M, Zepp F, Meyer CU, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles–mumps–rubella–varicella vaccine to children aged 11–21 months. Eur J Pediatr. 2010;169(8):925–933. doi: 10.1007/s00431-010-1142-6
   PubMed Web of Science ®Google Scholar
• Prymula R, Bergsaker MR, Esposito S, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383(9925):1313–1324. doi: 10.1016/S0140-6736(12)61461-5
   PubMed Web of Science ®Google Scholar
• Rüger G, Gabutti G, Rümke H, et al. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin. Pediatr Infect Dis J. 2012;31(11):1166–1172. doi: 10.1097/INF.0b013e318267fd8b
   PubMed Web of Science ®Google Scholar
• Rümke HC, Loch HP, Hoppenbrouwers K, et al. Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine. 2011;29(22):3842–3849. doi: 10.1016/j.vaccine.2011.02.067
   PubMed Web of Science ®Google Scholar
• Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27(8):724–730. doi: 10.1097/INF.0b013e318170bb22
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665–669. doi: 10.1097/01.inf.0000172902.25009.a1
   PubMed Web of Science ®Google Scholar
• Deichmann KA, Ferrera G, Tran C, et al. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants. Vaccine. 2015;33(20):2379–2386. doi: 10.1016/j.vaccine.2015.02.070
   PubMed Web of Science ®Google Scholar
• Kiely M, Billard MN, Toth E, et al. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. Vaccine. 2018;36(45):6688–6694. doi: 10.1016/j.vaccine.2018.09.049
   PubMed Web of Science ®Google Scholar
• Leonardi M, Bromberg K, Baxter R, et al. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics. 2011;128(6):e1387–e1394. doi: 10.1542/peds.2010-2132
   PubMed Web of Science ®Google Scholar
• Yetman RJ, Shepard JS, Duke A, et al. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children. Hum Vaccin Immunother. 2013;9(8):1691–1697. doi: 10.4161/hv.24873
   PubMed Web of Science ®Google Scholar
• Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr. 2007;166(8):857–864. doi: 10.1007/s00431-007-0506-z
   PubMed Web of Science ®Google Scholar
• Bonanni P, Boccalini S, Bechini A, et al. Co-administration of vaccines: a focus on tetravalent measles-mumps-rubella-varicella (MMRV) and meningococcal C conjugate vaccines. Hum Vaccin Immunother. 2020;16(6):1313–1321. doi: 10.1080/21645515.2019.1688032
   PubMed Web of Science ®Google Scholar
• Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345(9):656–661. doi: 10.1056/NEJMoa003077
   PubMed Web of Science ®Google Scholar
• Gold M, Dugdale S, Woodman RJ, et al. Use of the Australian childhood immunisation register for vaccine safety data linkage. Vaccine. 2010;28(26):4308–4311. doi: 10.1016/j.vaccine.2010.04.021
   PubMed Web of Science ®Google Scholar
• Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292(3):351–357. doi: 10.1001/jama.292.3.351
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke. Febrile seizures information page. [cited 2022 Jan 14]. Available from: https://www.ninds.nih.gov/Disorders/All-Disorders/Febrile-Seizures-Information-Page.
   Google Scholar
• Gabutti G, Kuhdari P, Ferioli S, et al. Hospital admissions for seizure in Italy: a decennial retrospective analysis with a special focus on the burden in the pediatric age. Neurol Sci. 2015;36(9):1667–1673. doi: 10.1007/s10072-015-2230-1
   PubMed Web of Science ®Google Scholar
• Opri R, Moretti U, Zanoni G XVI Relazione sull’attivita` del ‘‘Canale Verde’’. Dati relativi al 2012. [cited 2021 Sep 22]. Available from: https://www.ospedaleuniverona.it/extfiles/internet/93101/attachment/16a-relazione-dati-2012-17-07-13-finale.pdf.
   Google Scholar
• Gvozdenovic E, Vetter V, Willame C, et al. Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: post-hoc exploratory analysis of results from a matched-cohort study. Vaccine. 2018;36(39):5803–5806. doi: 10.1016/j.vaccine.2018.08.018
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Priorix-Tetra. [cited 2022 Aug 8]. Available from: https://gskpro.com/content/dam/global/hcpportal/en_NA/PI/Priorix-Tetra-GDS13.pdf.
   Google Scholar
• Monfries N, Goldman RD. Prophylactic antipyretics for prevention of febrile seizures following vaccination. Can Fam Physician. 2017;63(2):128–130.
   PubMed Web of Science ®Google Scholar
• Bauchau V, Van Holle L, Cohen C. Modelling hospitalisation ratios for febrile convulsions and severe varicella under combined measles, mumps, rubella, and varicella (MMRV—Priorix-Tetra™) compared to separate MMR + V vaccination. Drug Saf. 2015;38(11):1095–1102. doi: 10.1007/s40264-015-0326-4
   PubMed Web of Science ®Google Scholar
• Di Pietro A, Visalli G, Antonuccio GM, et al. Today’s vaccination policies in Italy: the National plan for vaccine prevention 2017-2019 and the law 119/2017 on the mandatory vaccinations. Ann Ig. 2019;31(2 Supple 1):54–64. doi: 10.7416/ai.2019.2277
   PubMed Web of Science ®Google Scholar
• Costantino C, Casuccio A, Sannasardo CE, et al. Public health strategies adopted to manage the increase of accesses to vaccination services, as a result of the application of the law 119/2017. Acta Biomed. 2020;91(3–S):35–40. doi: 10.23750/abm.v91i3-S.9413
   PubMedGoogle Scholar
• MacDonald SE, Tough S, Guo X, et al. Impact of combination MMRV vaccine on first-dose coverage for measles and varicella: a population-based study. J Public Health. 2022;30(5):1063–1068. doi: 10.1007/s10389-020-01379-9
   Google Scholar
• Vesikari T, Sadzot-Delvaux C, Rentier B, et al. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J. 2007;26(7):632–638. doi: 10.1097/INF.0b013e3180616c8f
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Buring JE. Epidemiology in medicine. 1 ed. Vol. 20. Philadelphia (USA): Lippincott Williams & Wilkins; 1987. (Mayrent SL. editor)
   Google Scholar
• Francis JR, Richmond P, Robins C, et al. An observational study of febrile seizures: the importance of viral infection and immunization. BMC Pediatr. 2016;16(1):202. doi: 10.1186/s12887-016-0740-5
   PubMed Web of Science ®Google Scholar
• Saada A, Lieu TA, Morain SR, et al. Parents’ choices and rationales for alternative vaccination schedules: a qualitative study. Clin Pediatr. 2015;54(3):236–243. doi: 10.1177/0009922814548838
   PubMed Web of Science ®Google Scholar
• Williams SE. What are the factors that contribute to parental vaccine-hesitancy and what can we do about it? Hum Vaccin Immunother. 2014;10(9):2584–2596. doi: 10.4161/hv.28596
   PubMed Web of Science ®Google Scholar
• Brown KF, Kroll JS, Hudson MJ, et al. Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine. 2010;28(26):4235–4248. doi: 10.1016/j.vaccine.2010.04.052
   PubMed Web of Science ®Google Scholar
• Tabacchi G, Costantino C, Napoli G, et al. Determinants of European parents’ decision on the vaccination of their children against measles, mumps and rubella: a systematic review and meta-analysis. Hum Vaccin Immunother. 2016;12(7):1909–1923. doi: 10.1080/21645515.2016.1151990
   PubMed Web of Science ®Google Scholar
• O’Leary ST, Suh CA, Marin M. Febrile seizures and measles–mumps–rubella–varicella (MMRV) vaccine: what do primary care physicians think? Vaccine. 2012;30(48):6731–6733. doi: 10.1016/j.vaccine.2012.08.075
   PubMed Web of Science ®Google Scholar